Alligator enters China’s ‘advancing’ market through licensing agreement

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Rainer Puster)
(Image: Getty/Rainer Puster)

Related tags: License, China, Bispecific antibodies, Antibody

Alligator grants Biotheus rights to an antibody for the creation of three bispecific molecules in the Greater China region.

The license agreement will see China-based Biotheus gain rights in the Republic of China, Hong kKong, Taiwan, and Macau to the antibody from Alligator Bioscience’s Alligator-Gold platform. Biotheus will use this antibody to develop three bispecific molecules.

In addition, the licensing agreement includes an option for Biotheus to expand its license to gain global rights to the antibody.

The antibody works against the tumor necrosis factor receptor (TNFR) family, which is a group of related receptors sharing sequence homology.

Per Norlén, CEO of Alligator, said in a statement that this collaboration with the Chinese biotech​ firm gives the company an entry into the “ fast advancing life science market in China.”

Biotheus will pay Alligator $1m (€900,000m) upfront in return for the licensing agreement, with $500,000 due at signing and the other $500,000 paid after six months of scientific and technical evaluation.

Alligator is eligible to receive milestones and option fees up to a total of $142m. If Biotheus chooses to exercise its option to gain global rights, it will pay $90m to Alligator,  plus royalties on future sales and a share of sub-license revenue.

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars